Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May-Jun;100(3):629-633.
doi: 10.1016/j.abd.2024.08.011. Epub 2025 Apr 10.

Pembrolizumab-induced Stevens-Johnson syndrome

Hiram Larangeira de Almeida Junior  1 , Debora Sarzi Sartori  2 , Aline Paganelli  3 , Karen Francisca Borges Sias  2 , Luísa Coelho Capuá  4 , Darlan Cleverson Farezin  4
Affiliations

Pembrolizumab-induced Stevens-Johnson syndrome

Hiram Larangeira de Almeida Junior et al. An Bras Dermatol. 2025 May-Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None declared.

Figures

Fig. 1
Fig. 1
(A) Erosions on the labial mucosa and malar regions. (B) Palmar lesions. (C) Target-like lesions on the abdomen.
Fig. 2
Fig. 2
Light microscopy with hematoxylin & eosin. (A) Epidermal detachment and light inflammatory reaction in the dermis (×100). (B) Detail of epidermal necrosis in the center of the lesion (×200). (C) Detail of the periphery of the lesion with isolated necrosis of keratinocytes and lymphocytic exocytosis (×200). (D) Lymphocyte satellitosis at the periphery of the lesion (×400).
Fig. 3
Fig. 3
Immunohistochemistry – low magnification (×40) showing light dermal infiltrate with positivity for CD3, CD4 and CD8 cells (A‒C), and negativity for CD20 (D).
Fig. 4
Fig. 4
Immunohistochemistry – detail (×400) showing stronger positivity in the dermis for CD3 and CD4 (A and B) and in the epidermis for CD3 (A) and CD8 (C). Negativity for CD20 (D).
See this image and copyright information in PMC

References

    1. Wei S.C., Duffy C.R., Allison J.P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086. - PubMed
    1. Johnson D.B., Nebhan C.A., Moslehi J.J., Balko J.M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254–267. - PMC - PubMed
    1. Watanabe T., Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023;14 - PMC - PubMed
    1. Ryu S., Jun I., Kim T.I., Seo K.Y., Kim E.K. Pembrolizumab-induced Stevens-Johnson syndrome with severe ocular complications. Ocul Immunol Inflamm. 2022;30:1533–1535. - PubMed
    1. Sandhu M, Kc B, Bhandari J, Gambhir HS, Farah R. Pembrolizumab-associated Stevens-Johnson syndrome in a patient with metastatic non-small cell lung cancer: a case report. Cureus. 2023;15 - PMC - PubMed

LinkOut - more resources